The global mosquito-borne infections testing market size accounted for USD 28.15 billion in 2025 and is forecasted to hit around USD 39.52 billion by 2034, representing a CAGR of 3.84% from 2025 to 2034. The Asia Pacific market size was estimated at USD 10.84 billion in 2024 and is expanding at a CAGR of 3.98% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Mosquito-Borne Infections Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Mosquito-Borne Infections Testing Market, by Disease Type
8.1.1. Malaria
8.1.1.1. Market Revenue and Forecast
8.1.2. Dengue
8.1.2.1. Market Revenue and Forecast
8.1.3. Zika Virus
8.1.3.1. Market Revenue and Forecast
8.1.4. Chikungunya
8.1.4.1. Market Revenue and Forecast
8.1.5. Yellow Fever
8.1.5.1. Market Revenue and Forecast
8.1.6. West Nile Virus
8.1.6.1. Market Revenue and Forecast
8.1.7. Others (Japanese encephalitis, Rift Valley fever, etc.)
8.1.7.1. Market Revenue and Forecast
9.1. Mosquito-Borne Infections Testing Market, by Test Type
9.1.1. Molecular Tests
9.1.1.1. Market Revenue and Forecast
9.1.2. Serological Tests
9.1.2.1. Market Revenue and Forecast
9.1.3. Immunoassays
9.1.3.1. Market Revenue and Forecast
9.1.4. Next Generation Sequencing (NGS)
9.1.4.1. Market Revenue and Forecast
9.1.5. Others (e.g., CRISPR-based diagnostics)
9.1.5.1. Market Revenue and Forecast
10.1. Mosquito-Borne Infections Testing Market, by Sample Type
10.1.1. Blood
10.1.1.1. Market Revenue and Forecast
10.1.2. Serum/Plasma
10.1.2.1. Market Revenue and Forecast
10.1.3. Saliva/Urine
10.1.3.1. Market Revenue and Forecast
10.1.4. Others (e.g., cerebrospinal fluid)
10.1.4.1. Market Revenue and Forecast
11.1. Mosquito-Borne Infections Testing Market, by End User
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast
11.1.3. Public Health Agencies
11.1.3.1. Market Revenue and Forecast
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast
11.1.5. Point-of-Care/Field Testing
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. Mosquito-Borne Infections Testing Market, by Technology
12.1.1. Nucleic Acid Amplification Techniques (NAAT)
12.1.1.1. Market Revenue and Forecast
12.1.2. Immunochromatographic Techniques
12.1.2.1. Market Revenue and Forecast
12.1.3. Microfluidics-based Diagnostics
12.1.3.1. Market Revenue and Forecast
12.1.4. Biosensor Platforms
12.1.4.1. Market Revenue and Forecast
12.1.5. Others
12.1.5.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type
13.1.2. Market Revenue and Forecast, by Test Type
13.1.3. Market Revenue and Forecast, by Sample Type
13.1.4. Market Revenue and Forecast, by End User
13.1.5. Market Revenue and Forecast, by Technology
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type
13.1.6.2. Market Revenue and Forecast, by Test Type
13.1.6.3. Market Revenue and Forecast, by Sample Type
13.1.6.4. Market Revenue and Forecast, by End User
13.1.6.5. Market Revenue and Forecast, by Technology
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease Type
13.1.7.2. Market Revenue and Forecast, by Test Type
13.1.7.3. Market Revenue and Forecast, by Sample Type
13.1.7.4. Market Revenue and Forecast, by End User
13.1.7.5. Market Revenue and Forecast, by Technology
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type
13.2.2. Market Revenue and Forecast, by Test Type
13.2.3. Market Revenue and Forecast, by Sample Type
13.2.4. Market Revenue and Forecast, by End User
13.2.5. Market Revenue and Forecast, by Technology
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type
13.2.6.2. Market Revenue and Forecast, by Test Type
13.2.6.3. Market Revenue and Forecast, by Sample Type
13.2.7. Market Revenue and Forecast, by End User
13.2.8. Market Revenue and Forecast, by Technology
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type
13.2.9.2. Market Revenue and Forecast, by Test Type
13.2.9.3. Market Revenue and Forecast, by Sample Type
13.2.10. Market Revenue and Forecast, by End User
13.2.11. Market Revenue and Forecast, by Technology
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type
13.2.12.2. Market Revenue and Forecast, by Test Type
13.2.12.3. Market Revenue and Forecast, by Sample Type
13.2.12.4. Market Revenue and Forecast, by End User
13.2.13. Market Revenue and Forecast, by Technology
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type
13.2.14.2. Market Revenue and Forecast, by Test Type
13.2.14.3. Market Revenue and Forecast, by Sample Type
13.2.14.4. Market Revenue and Forecast, by End User
13.2.15. Market Revenue and Forecast, by Technology
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type
13.3.2. Market Revenue and Forecast, by Test Type
13.3.3. Market Revenue and Forecast, by Sample Type
13.3.4. Market Revenue and Forecast, by End User
13.3.5. Market Revenue and Forecast, by Technology
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type
13.3.6.2. Market Revenue and Forecast, by Test Type
13.3.6.3. Market Revenue and Forecast, by Sample Type
13.3.6.4. Market Revenue and Forecast, by End User
13.3.7. Market Revenue and Forecast, by Technology
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type
13.3.8.2. Market Revenue and Forecast, by Test Type
13.3.8.3. Market Revenue and Forecast, by Sample Type
13.3.8.4. Market Revenue and Forecast, by End User
13.3.9. Market Revenue and Forecast, by Technology
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type
13.3.10.2. Market Revenue and Forecast, by Test Type
13.3.10.3. Market Revenue and Forecast, by Sample Type
13.3.10.4. Market Revenue and Forecast, by End User
13.3.10.5. Market Revenue and Forecast, by Technology
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type
13.3.11.2. Market Revenue and Forecast, by Test Type
13.3.11.3. Market Revenue and Forecast, by Sample Type
13.3.11.4. Market Revenue and Forecast, by End User
13.3.11.5. Market Revenue and Forecast, by Technology
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type
13.4.2. Market Revenue and Forecast, by Test Type
13.4.3. Market Revenue and Forecast, by Sample Type
13.4.4. Market Revenue and Forecast, by End User
13.4.5. Market Revenue and Forecast, by Technology
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type
13.4.6.2. Market Revenue and Forecast, by Test Type
13.4.6.3. Market Revenue and Forecast, by Sample Type
13.4.6.4. Market Revenue and Forecast, by End User
13.4.7. Market Revenue and Forecast, by Technology
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type
13.4.8.2. Market Revenue and Forecast, by Test Type
13.4.8.3. Market Revenue and Forecast, by Sample Type
13.4.8.4. Market Revenue and Forecast, by End User
13.4.9. Market Revenue and Forecast, by Technology
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type
13.4.10.2. Market Revenue and Forecast, by Test Type
13.4.10.3. Market Revenue and Forecast, by Sample Type
13.4.10.4. Market Revenue and Forecast, by End User
13.4.10.5. Market Revenue and Forecast, by Technology
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type
13.4.11.2. Market Revenue and Forecast, by Test Type
13.4.11.3. Market Revenue and Forecast, by Sample Type
13.4.11.4. Market Revenue and Forecast, by End User
13.4.11.5. Market Revenue and Forecast, by Technology
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type
13.5.2. Market Revenue and Forecast, by Test Type
13.5.3. Market Revenue and Forecast, by Sample Type
13.5.4. Market Revenue and Forecast, by End User
13.5.5. Market Revenue and Forecast, by Technology
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type
13.5.6.2. Market Revenue and Forecast, by Test Type
13.5.6.3. Market Revenue and Forecast, by Sample Type
13.5.6.4. Market Revenue and Forecast, by End User
13.5.7. Market Revenue and Forecast, by Technology
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type
13.5.8.2. Market Revenue and Forecast, by Test Type
13.5.8.3. Market Revenue and Forecast, by Sample Type
13.5.8.4. Market Revenue and Forecast, by End User
13.5.8.5. Market Revenue and Forecast, by Technology
14.1. Abbott Laboratories
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Thermo Fisher Scientific
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bio-Rad Laboratories
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. F. Hoffmann-La Roche AG
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Siemens Healthineers
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Becton, Dickinson and Company (BD)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. bioMérieux SA
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Qiagen N.V.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Danaher Corporation (Cepheid)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck KGaA
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description